Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance

Enhanced Sensitivity of Cancer Stem Cells to Chemotherapy Using Functionalized Mesoporous Silica Nanoparticles

“…ABCG2 gene silencing using short hairpin RNA (shRNA) is a promising therapeutic approach for overcoming drug resistance [12][13][14] . Nanoparticle-mediated gene delivery has demonstrated enhanced transfection efficacy due to the structure, size, and surface properties of the nanoparticles 15,16 , allowing them to readily accumulate in and be retained by solid tumors through the enhanced permeability and retention (EPR) effect 17,18 .…”

Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo

“…3A). It suggests that poly-siRNA/tGC nanoparticles containing reducible disulphide linkages could be rapidly reduced and restored to native siRNA monomeric form without any therapeutic activity loss [17,27]. Importantly, the Dual-NP-treated cells simultaneously reduced both mRNA levels of VEGF and Bcl-2 in the cell culture system.…”

Biodistribution and Pharmacokinetics of Mad2 siRNA-loaded EGFR-Targeted Chitosan Nanoparticles in Cisplatin Sensitive and Resistant Lung Cancer Models

“…At different time points (12,24,48,72,96 and 120 h), animals were sacrificed and blood samples, the major organs (liver, spleen, lung, heart, kidney), and tumors were collected. Blood samples from the facial vein were also collected 6 h after injection.…”

“…Enzymatic degradation, removal from circulation by renal excretion or mononuclear phagocyte system (MPS), poor cellular uptake and endosomal release are examples of physiological barriers that siRNAs need to overcome [17,18]. Several viral and nonviral delivery vectors, such as adenovirus, polyplexes, liposomes, and micelles, amongst others, have been developed to overcome these obstacles and improve RNAi therapeutic efficacy in vivo [19][20][21][22][23][24][25].…”